methotrexate has been researched along with Myelomonocytic Leukemia, Chronic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Dreger, P; Hegenbart, U; Herfarth, K; Luft, T; Müller-Tidow, C; Radujkovic, A | 1 |
| Hannon, M; Kasner, M; Nwaoduah, N; Wilde, L | 1 |
| Akiyama, Y; Koike, K; Kojima, S; Manabe, A; Nakahata, T; Okamura, J; Saito, T; Sako, M; Uchiyama, H; Yumura-Yagi, K | 1 |
3 other study(ies) available for methotrexate and Myelomonocytic Leukemia, Chronic
| Article | Year |
|---|---|
High leukemia-free survival after TBI-based conditioning and mycophenolate mofetil-containing immunosuppression in patients allografted for chronic myelomonocytic leukemia: a single-center experience.
Topics: Adult; Aged; Antilymphocyte Serum; Busulfan; Calcineurin Inhibitors; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Melphalan; Methotrexate; Middle Aged; Mycophenolic Acid; Myeloablative Agonists; Neoplasms, Second Primary; Proportional Hazards Models; Retrospective Studies; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2020 |
Chronic myelomonocytic leukemia with central nervous system involvement.
Topics: Antimetabolites, Antineoplastic; Central Nervous System; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Chronic; Leukocytosis; Male; Methotrexate; Middle Aged; Monocytes; Treatment Outcome | 2018 |
Allogeneic hematopoietic stem cell transplantation for 27 children with juvenile myelomonocytic leukemia diagnosed based on the criteria of the International JMML Working Group.
Topics: Adolescent; Bone Marrow; Child; Child, Preschool; Combined Modality Therapy; Disease-Free Survival; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; HLA-A Antigens; Humans; Immunosuppressive Agents; Infant; Infant, Newborn; Karyotyping; Leukemia, Myelomonocytic, Chronic; Male; Methotrexate; Prognosis; Retrospective Studies; Risk Factors; Survival Rate; Transplantation, Homologous | 2002 |